HYpofractionated, dose-redistributed RAdiotherapy (HYDRA) versus conventional radiotherapy for head and neck cancer: planned interim analysis and dosimetric comparison from the phase I HYDRA trial
The predefined interim analysis of HYDRA-photons showed one DLT. Per protocol, inclusion of laryngeal carcinomas in the photon cohort is now possible. The 20 fraction HYDRA schedule delivers a focal boost to the tumour with reduced dose to all organs at risk.
Authors
- Michiel Kroesen (ORCID: https://orcid.org/0000-0002-1346-2277)
- Remi A. Nout (ORCID: https://orcid.org/0000-0001-8011-2982)
- Joris B.W. Elbers (ORCID: https://orcid.org/0000-0003-1537-4139)
- Mischa S. Hoogeman (ORCID: https://orcid.org/0000-0002-4264-9903)
- Erik D. van Werkhoven (ORCID: https://orcid.org/0000-0001-7469-7427)
- Gerda M. Verduijn (ORCID: https://orcid.org/0000-0002-3513-6544)
- Stijn Keereweer (ORCID: https://orcid.org/0000-0003-4665-6868)
- Pascal A. Gunsch
- Jaap Zindler (ORCID: https://orcid.org/0000-0002-3084-4568)
- Esther van Meerten
- Reno Debets
Institutions
- Medisch Centrum Haaglanden (NL)
- Erasmus MC Cancer Institute (NL)
- Delft University of Technology (NL)
Publication Details
- Journal
- Clinical and Translational Radiation Oncology
- Published
- 2026-01-25
- DOI
- https://doi.org/10.1016/j.ctro.2026.101113
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00